The Recall Desk
HighFDA (Drugs)·D-0512-2024·Announced 2024-06-05

Epinephrine-Lidocaine Intraocular Injection Vials Recalled for Sterility Assurance

Imprimis NJOF, LLC is recalling 14,180 vials of Epinephrine-Lidocaine intraocular injection due to lack of assurance of sterility. These vials were distributed nationwide within the United States.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA Class II recall of a pharmaceutical product with sterility assurance defect. No reported illnesses or hospitalizations mentioned in the source text. This meets the criterion for Score 3: a risk-of-harm product where injury has not yet been reported.

Plain-English summary

The U.S. Food and Drug Administration has issued a Class II recall of Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free 1mL Single-Use vials for intraocular injection. The product is manufactured by Imprimis NJOF, LLC of Ledgewood, New Jersey.

The recall was initiated due to lack of assurance of sterility. The recall affects two lots: 23APR033 (expiration date May 1, 2024) and 23JUN001 (expiration date June 5, 2024). In total, 14,180 vials were distributed nationwide within the United States.

The recalled product

Product
Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free 1mL Single-Use vials for Intraocular Injection, Imprimis NJOF, LLC. 1705 Route 46 West, unit 6B, Ledgewood, NJ 07852, NDC 71384-640-01
Manufacturer
Imprimis NJOF, LLC
Hazard
  • sterility

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (4)

  • Lot #: 23APR033
  • Exp. Date 5/1/24
  • 23JUN001
  • Exp. Date 6/5/24

Distribution

Distributed nationwide across the United States.